NAYA Therapeutics is a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of astatine-211 targeted alpha therapies
and NK-cell-engaging bifunctional antibodies.


We aim to unlock deeper, more durable responses in patients not responding to current standard-of-care, with an initial focus on hepatocellular carcinoma (HCC) and multiple myeloma.